Zietman AL - Search Results

1

Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.

Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ 3rd, Toonkel LM, Zietman AL, Tanguay S, Sandler HM. Kaufman DS, et al. Among authors: zietman al. Urology. 2009 Apr;73(4):833-7. doi: 10.1016/j.urology.2008.09.036. Epub 2008 Dec 18. Urology. 2009. PMID: 19100600 Clinical Trial.

2

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome.

Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Zietman AL, et al. J Urol. 1994 Mar;151(3):640-5. doi: 10.1016/s0022-5347(17)35036-x. J Urol. 1994. PMID: 7508522

3

The effect of pelvic radiation therapy on serum levels of prostate specific antigen.

Willett CG, Zietman AL, Shipley WU, Coen JJ. Willett CG, et al. Among authors: zietman al. J Urol. 1994 Jun;151(6):1579-81. doi: 10.1016/s0022-5347(17)35306-5. J Urol. 1994. PMID: 7514692

4

Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome.

Zietman AL, Edelstein RA, Coen JJ, Babayan RK, Krane RJ. Zietman AL, et al. Urology. 1994 Jun;43(6):828-33. doi: 10.1016/0090-4295(94)90144-9. Urology. 1994. PMID: 7515206

5

Re: The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

Zietman AL, Shipley WU. Zietman AL, et al. J Urol. 1994 Nov;152(5 Pt 1):1564-5; author reply 1565-6. J Urol. 1994. PMID: 7523713 No abstract available.

6

Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.

Zietman AL, Shipley WU, Coen JJ. Zietman AL, et al. J Urol. 1994 Nov;152(5 Pt 2):1806-12. doi: 10.1016/s0022-5347(17)32389-3. J Urol. 1994. PMID: 7523726 Review.

7

Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications.

Zietman AL, Shipley WU, Willett CG. Zietman AL, et al. Cancer. 1993 Feb 1;71(3 Suppl):959-69. doi: 10.1002/1097-0142(19930201)71:3+<959::aid-cncr2820711411>3.0.co;2-l. Cancer. 1993. PMID: 7679046 Review.

8

Adjuvant irradiation after radical prostatectomy for adenocarcinoma of prostate: analysis of freedom from PSA failure.

Zietman AL, Coen JJ, Shipley WU, Althausen AF. Zietman AL, et al. Urology. 1993 Sep;42(3):292-8; discussion 298-9. doi: 10.1016/0090-4295(93)90618-k. Urology. 1993. PMID: 7691014

9

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.

Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al. Shipley WU, et al. Among authors: zietman al. Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):3-12. doi: 10.1016/0360-3016(95)00063-5. Int J Radiat Oncol Biol Phys. 1995. PMID: 7721636 Clinical Trial.

10

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome.

Zietman AL, Coen JJ, Dallow KC, Shipley WU. Zietman AL, et al. Int J Radiat Oncol Biol Phys. 1995 May 15;32(2):287-92. doi: 10.1016/0360-3016(95)00123-G. Int J Radiat Oncol Biol Phys. 1995. PMID: 7751173

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

366 results

Search Page

Filters